Results 141 to 150 of about 62,276 (286)

Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID‐19

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 922-935, October 2026.
ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio   +38 more
wiley   +1 more source

FIBRINOLYSIS AND ATHEROSCLEROSIS - AN UPDATE

open access: yes, 1994
HAMSTEN, A, ERIKSSON, P
core   +1 more source

An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia

open access: yesLiver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background & Aims Conventional laboratory tests do not capture platelet–vessel wall interactions (primary haemostasis) occurring in vivo, limiting guidance before invasive procedures. This is relevant in patients with thrombocytopenia, hallmark of advanced cirrhosis. Microfluidic assays may overcome these limitations.
Niccolò Bitto   +14 more
wiley   +1 more source

Reference Intervals for ROTEM-tPA: Whole-Blood Fibrinolysis Assessment in Healthy Adults. [PDF]

open access: yesTH Open
Malte AL   +6 more
europepmc   +1 more source

Obesity‐Related Coagulation Activation in Adolescents and Children: A Systematic Review and Meta‐Analysis

open access: yesObesity Reviews, Volume 27, Issue 10, October 2026.
Obesity is widely recognized as a pro‐thrombotic condition, yet the specific biomarker profile reflecting coagulation activation remains incompletely defined. Obesity is associated with increased coagulation activation, particularly in children, suggesting an early pro‐thrombotic shift.
Julia Buchold   +9 more
wiley   +1 more source

Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes

open access: yesPediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Background Type 1 plasminogen deficiency (PLGD‐1) is an ultra‐rare autosomal recessive disorder caused by variants in the PLG gene and affects approximately 1.6 individuals per million. The condition is characterized by decreased plasminogen levels and impaired function, resulting in fibrin‐rich lesions on mucous membranes throughout the body.
Charles Nakar   +7 more
wiley   +1 more source

Patterned ELR‐Gelatin Hydrogels Enable Rapid Endothelial Monolayer Formation via Bioactive Matrix Chemistry and Surface Topography

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 34, 11 September 2026.
Micro‐ and nano‐patterned elastin‐like recombinamer (ELR) hydrogels integrate bioactive matrix chemistry with defined surface topography. The combined cues promote rapid endothelial cell capture, alignment, and monolayer formation on soft substrates.
Jagoda Litowczenko   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy